Wednesday, February 10, 2010, 7:11am EST - Canadian Markets open in 2 hours and 19 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Keryx Biopharmaceuticals Inc. (KERX)

 On Feb 9: 2.31 USD   0.00 (0.00%)  
MORE ON KERX
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Keryx Biopharmaceuticals, Inc. (NCM:KERX) Delayed quote dataEdit
Last Trade: 2.31 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 2.31
Open: N/A
Bid: 2.19 x 200
Ask: 2.88 x 1000
1y Target Est: 5.00
Day's Range: N/A - N/A
52wk Range: 0.09 - 3.45
Volume: 0
Avg Vol (3m): 1,774,390
Market Cap: 129.31M
P/E (ttm): 9.75
EPS (ttm): 0.24
Div & Yield: N/A (N/A%)
Keryx Biopharmaceuticals Inc. (KERX)
1d  5d  3m  6m  1y  2y  5y  max 
 Add KERX to Portfolio   Download Data

HEADLINES
• A Triple in the Making
at Motley Fool (Mon, Feb 8)
• Keryx Biopharmaceuticals (NASDAQ: KERX) Responds to Erroneous Report About Planned Phase III Study for Patients With Colorectal Cancer
Marketwire (Fri, Feb 5)
• Biotech Stock Mailbag: Soligenix
at TheStreet.com (Fri, Feb 5)
• Keryx, FDA agree on colon cancer drug study goals
AP (Wed, Feb 3)
• Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patie
PRNewswire (Wed, Feb 3)
• Keryx Biopharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
PRNewswire (Tue, Feb 2)
• Keryx, AEterna see positive perifosine data
AP (Fri, Jan 29)
• Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglo
PRNewswire (Fri, Jan 29)
• Biotech Stock Mailbag: Keryx Biopharmaceuticals
at TheStreet.com (Fri, Jan 29)
• Keryx Biopharmaceuticals, Inc. Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 in the Treatment of Advanced Metastatic Colon Cancer - Call scheduled for 9:00 am ET today
CCBN (Thu, Jan 28)
More Headlines for KERX...
ANALYST
EPS Est (next year) (Dec-09) : 0.23
EPS Est (in 2 years) (Dec-10) : -0.26
Avg Rec (current)*: 1.0
PEG Ratio: 0.36
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices